Up­dat­ed: GSK nabs pri­or­i­ty re­view on RSV vac­cine, kicks off show­down with Pfiz­er — while 'set­ting the bar high' on R&D

GSK ap­pears to have beat­en Pfiz­er in get­ting a BLA for its RSV vac­cine in front of the FDA, se­cur­ing pri­or­i­ty re­view for the use of its jab among old­er adults.

CEO Em­ma Walm­s­ley spot­light­ed the RSV vac­cine can­di­date in a me­dia call Wednes­day, say­ing that GSK is “in­cred­i­bly con­fi­dent” about its ef­fi­ca­cy and the “tremen­dous com­mer­cial op­por­tu­ni­ty” it rep­re­sents.

With the spin­out of the con­sumer health­care busi­ness in­to Ha­le­on, and Tony Wood fill­ing the CSO po­si­tion pre­vi­ous­ly filled by Hal Bar­ron, Walm­s­ley re­mains up­beat. She ar­gued that GSK is in a “far bet­ter po­si­tion” than it was when it laid out its R&D strat­e­gy four years ago, with a heavy fo­cus on im­munol­o­gy and on­col­o­gy as well as tech­nol­o­gy and da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER